Biogen | BIIB - Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
ALKERMES USD 165.61M 503K 2025-12
Amgen USD 539M 1000K 2025-12
Bayer EUR 982.42M 0 2025-12
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 946.83M 354.23M 2025-06
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Gilead Sciences USD 1.24B 1000K 2025-12
Incyte USD 198.46M 2.33M 2025-12
Merck USD 2.49B 15.79M 2025-09
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.91B 10.64M 2025-12
Pfizer USD 5.69B 1000K 2025-09
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Sarepta Therapeutics USD 104.96M 196K 2025-12
Teva Pharmaceutical Industries USD 1.15B 0 2025-12
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
United Therapeutics USD 43.64M 740K 2025-12
Vertex Pharmaceuticals USD 254M 0 2025-12